Morning Buzz: Halliburton Company, Petroleo Brasileiro, Eli Lilly & Co


Follow this company

Companies Mentioned

NYSE:LLY / NYSE:HAL
03/08/2013 [ACCESSWIRE]

NEW YORK, March 08, 2013 - vb-news.net, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Halliburton Company, Petroleo Brasileiro, Eli Lilly & Co.

Halliburton Company(NYSE:HAL), which provides hydraulic fracturing services, has managed to boost savings to as much as $400,000 annually by using recycled water in its drilling process.

Walter Dale, who heads Halliburton's water management services, told Bloomberg that the company had altered the chemistry of the water, chemical and sand combination blasted underground to free trapped hydrocarbons, increasing savings from about $6,000 a well in 2011 to as much as $400,000 in 2012 for some wells in North Dakota.

Is HAL On The Way To Move Back To New highs? Get Free Trend Analysis Here http://vbtrendreport.com/aw/?code=HAL

The average cost of drilling in North Dakota's Bakken field wells is about $10 million, according to Hess Corp.

The Bloomberg report said that "as local and federal regulators raise questions about water consumption from drilling operations, U.S. oil and natural gas producers are asking service companies to improve their handling of the millions of gallons of fluids involved in fracking an average well."

Dale said that the company's goal was to ensure that the oil and gas industry used 25 percent less fresh water in fracking jobs by the end of 2014. 

Credit Suisse has upgraded Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) to Outperform from Neutral, a day after the company surprised the market by raising diesel prices.

Has PBR Reached The Bottom and Ready To Move Up? Find Out Here http://vbtrendreport.com/aw/?code=PBR

Analysts from CS said that they were now more optimistic about the company after maintaining a cautious stance for more than two years.

Explaining the upgrade CS analysts said, "A big step was taken yesterday: PBR increased diesel prices just ahead of a Central Bank meeting, precisely at time when inflation is at the forefront of politicians’ minds. This could be the beginning of a more benign Government attitude, trying to restore business confidence. Other anecdotal evidence can be found in infrastructure, utilities (potential fund to handle tariff review) and banks (Basel III measures and change in provisioning taxation rules).

Drug maker Eli Lilly & Co.(NYSE:LLY) and Kowa Pharmaceuticals said that studies had shown that drug Livalo was better at lowering bad cholesterol in those infected with HIV than Pravastatin.

Is LLY a Buy At New highs? Let’s Find Out Here http://vbtrendreport.com/aw/?code=LLY

The study showed that after four weeks four milligrams of Livalo, or pitavastatin, reduced low-density lipoprotein cholesterol 31 percent in HIV-infected adults with high cholesterol, or dyslipidemia, compared with a 21 percent reduction in LDL-C levels for those taking 40 milligrams of pravastatin.

The study was designed as a superiority trial and met its primary endpoint.

About vb-news.net

vb-news.net’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer

The assembled information disseminated by vb-news.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vb-news.net does expect that investors will buy and sell securities based on information assembled and presented in vb-news.net. PLEASE always do your own due diligence, and consult your financial advisor.

Contacts:

vb-news.net
1419 Westwood Blvd Los Angeles, CA
90024-4911
staff@vb-news.net
www.vb-news.net
COMMENTS

Leave a comment...
 * 

Your Name
 *